stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Gross margin
Tarsus Pharmaceuticals, Inc.'s gross margin over the twelve months to 30 September 2026 was 93.2%, up 0.0 percentage points from fiscal 2025 (93.2%). Over the past ten years it has ranged from 0.00% (fiscal 2020) to 96.4% (fiscal 2021); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 93.2% | 0.21 |
| FY2024 | 93.0% | 2.12 |
| FY2023 | 90.9% | (5.43) |
| FY2022 | 96.3% | (0.06) |
| FY2021 | 96.4% | 96.36 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 92.9% | (0.17) |
| Jun 2026 | 93.0% | (1.17) |
| Mar 2026 | 94.2% | 1.40 |
| Dec 2025 | 92.8% | (0.20) |
| 23 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| VRDN Viridian Therapeutics, Inc. compare | 100.0% |
| DNLI Denali Therapeutics Inc. compare | 98.7% |
| TARS Tarsus Pharmaceuticals, Inc. | 93.2% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 90.5% |
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement